The latest update is out from Aquestive Therapeutics ( (AQST) ).
Aquestive Therapeutics reports a positive financial outlook with a cash runway into 2026 and advances in its innovative pharmaceutical pipeline. The company is progressing towards a pre-NDA meeting for Anaphylm, an oral epinephrine treatment, and planning a Phase 2a study for AQST-108, a topical gel for alopecia areata. Libervant, its FDA-approved buccal film for seizures in young children, has expanded market reach. Aquestive’s strategic developments and robust financial health make it an attractive prospect for investors interested in pharmaceutical innovations.
For an in-depth examination of AQST stock, go to TipRanks’ Stock Analysis page.
